Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Two Decades of Progress in the Prevention and Treatment of...
share announcement

Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 7241

Special Issue Editors

Dr. Manish Tripathi

E-Mail Website
Guest Editor
1. Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA
2. South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX 78504, USA
Interests: cancer progression; metastasis; lncRNA; transcription regulation; drug resistance; anoikis; CRC; HCC
Dr. Puneet Vij

E-Mail Website
Guest Editor
1. Department of Pharmaceutical Sciences, St. John’s University, Queens, NY 11432, USA
2. Michigan Public Health Institute, Okemos, MI 48842, USA
Interests: colon cancer; cancer biomarkers; resistance; immunotherapy

Special Issue Information

Dear Colleagues,

This Special Issue, “Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy”, aims to provide a comprehensive overview of the advancements made in the field of colorectal cancer prevention and treatment over the past two decades. This Special Issue intends to gather cutting-edge research, review articles, and expert opinions that highlight the significant milestones, breakthroughs, and emerging trends in the management of colorectal cancer.

The scope of this Special Issue includes, but is not limited to, the following topics:

  • Introduction to colorectal cancer: molecular pathways;
  • Chemoprevention: mechanisms and effectiveness of various chemopreventive agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and certain dietary components, in reducing the risk of colorectal cancer;
  • Advances in screening and early detection of colorectal cancer: molecular markers, imaging techniques, and non-invasive tests. liquid biopsy: circulating tumor DNA (ctDNA), microRNAs, and other molecular markers present in blood or other bodily fluids as potential tools for noninvasive monitoring and assessment of colorectal cancer;
  • Development and clinical application of targeted therapies for colorectal cancer: EGFR inhibitors, VEGF inhibitors, combinatorial therapy, and BRAF inhibitors;
  • Immunotherapy approaches in colorectal cancer: checkpoint inhibitors, CAR-T cell therapy, and vaccine strategies;
  • Personalized medicine and precision oncology in colorectal cancer: tailor treatments to individual patients based on their unique characteristics, predictive biomarkers, and the genetic and molecular profile of the tumor. Integration of genomic, transcriptomic, epigenomic, and proteomic data can provide a comprehensive understanding of the tumor;
  • Emerging therapeutic strategies: combination therapies, immunogenomics, and novel drug targets;
  • Overcoming resistance to treatment in colorectal cancer: resistance to various therapies can develop, including chemotherapy, targeted therapies, and immunotherapies. Strategies to address resistance in colorectal cancer;
  • Implementation of colorectal cancer prevention and treatment guidelines: challenges and future directions.

Dr. Manish Tripathi
Dr. Puneet Vij
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • biomarkers
  • colorectal cancer
  • targeted therapies
  • molecular pathways
  • resistance
  • personalized medicine
  • genomic profiling
  • chemoprevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 2114 KiB  
Article
Two Decades of Progress in Personalized Medicine of Colorectal Cancer in Serbia—Insights from the Institute for Oncology and Radiology of Serbia
by Milena Cavic, Neda Nikolic, Mladen Marinkovic, Ana Damjanovic, Ana Krivokuca, Miljana Tanic, Marko Radulovic, Aleksandra Stanojevic, Luka Pejnovic, Marija Djordjic Crnogorac, Ana Djuric, Miodrag Vukovic, Vanja Stevanovic, Jelena Kijac, Valentina Karadzic, Srdjan Nikolic, Suzana Stojanovic-Rundic, Radmila Jankovic and Jelena Spasic
Biomedicines 2024, 12(10), 2278; https://doi.org/10.3390/biomedicines12102278 - 8 Oct 2024
Viewed by 1570
Abstract
Background: It is projected that, by 2040, the number of new cases of colorectal cancer (CRC) will increase to 3.2 million, and the number of deaths to 1.6 million, highlighting the need for prevention strategies, early detection and adequate follow-up. In this study, [...] Read more.
Background: It is projected that, by 2040, the number of new cases of colorectal cancer (CRC) will increase to 3.2 million, and the number of deaths to 1.6 million, highlighting the need for prevention strategies, early detection and adequate follow-up. In this study, we aimed to provide an overview of the progress in personalized medicine of CRC in Serbia, with results and insights from the Institute for Oncology and Radiology of Serbia (IORS), and to propose guidance for tackling observed challenges in the future. Methods: Epidemiological data were derived from official global and national cancer registries and IORS electronic medical records. Germline genetic testing for Lynch syndrome was performed by Next Generation Sequencing. RAS and BRAF mutation analyses were performed using qPCR diagnostic kits. Results: Epidemiology and risk factors, prevention and early detection programs, as well as treatment options and scientific advances have been described in detail. Out of 103 patients who underwent germline testing for Lynch syndrome, 19 (18.4%) showed a mutation in MMR genes with pathogenic or likely pathogenic significance and 8 (7.8%) in other CRC-associated genes (APC, CHEK2, MUTYH). Of 6369 tested patients, 50.43% had a mutation in KRAS or NRAS genes, while 9.54% had the V600 mutation in the BRAF gene. Conclusions: Although significant improvements in CRC management have occurred globally in recent years, a strategic approach leading to population-based systemic solutions is required. The high incidence of young-onset CRC and the growing elderly population due to a rise in life expectancy will be especially important factors for countries with limited healthcare resources like Serbia. Full article
(This article belongs to the Special Issue Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy)
►▼ Show Figures

Figure 1

22 pages, 3595 KiB  
Article
Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer
by Jimmy Stalin, Oriana Coquoz, Rachel Jeitziner Marcone, Stephane Jemelin, Nina Desboeufs, Mauro Delorenzi, Marcel Blot-Chabaud, Beat A. Imhof and Curzio Ruegg
Biomedicines 2023, 11(12), 3185; https://doi.org/10.3390/biomedicines11123185 - 30 Nov 2023
Viewed by 1539
Abstract
The melanoma cell adhesion molecule, shed from endothelial and cancer cells, is a soluble growth factor that induces tumor angiogenesis and growth. However, the molecular mechanism accounting for its generation in a tumor context is still unclear. To investigate this mechanism, we performed [...] Read more.
The melanoma cell adhesion molecule, shed from endothelial and cancer cells, is a soluble growth factor that induces tumor angiogenesis and growth. However, the molecular mechanism accounting for its generation in a tumor context is still unclear. To investigate this mechanism, we performed in vitro experiments with endothelial/cancer cells, gene expression analyses on datasets from human colorectal tumor samples, and applied pharmacological methods in vitro/in vivo with mouse and human colorectal cancer cells. We found that soluble MCAM generation is governed by ADAM17 proteolytic activity and NOX1-regulating ADAM17 expression. The treatment of colorectal tumor-bearing mice with pharmacologic NOX1 inhibitors or tumor growth in NOX1-deficient mice reduced the blood concentration of soluble MCAM and abrogated the anti-tumor effects of anti-soluble MCAM antibodies while ADAM17 pharmacologic inhibitors reduced tumor growth and angiogenesis in vivo. Especially, the expression of MCAM, NOX1, and ADAM17 was more prominent in the angiogenic, colorectal cancer-consensus molecular subtype 4 where high MCAM expression correlated with angiogenic and lymphangiogenic markers. Finally, we demonstrated that soluble MCAM also acts as a lymphangiogenic factor in vitro. These results identify a role for NOX1/ADAM17 in soluble MCAM generation, with potential clinical therapeutic relevance to the aggressive, angiogenic CMS4 colorectal cancer subtype. Full article
(This article belongs to the Special Issue Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 2361 KiB  
Review
New Horizons in Cancer Progression and Metastasis: Hippo Signaling Pathway
by Murali R. Kuracha, Uppala Radhakrishna, Sreenaga V. Kuracha, Navyasri Vegi, Jhyama Lhamo Gurung and Benita L. McVicker
Biomedicines 2024, 12(11), 2552; https://doi.org/10.3390/biomedicines12112552 - 8 Nov 2024
Viewed by 987
Abstract
The Hippo pathway is highly evolved to maintain tissue homeostasis in diverse species by regulating cell proliferation, differentiation, and apoptosis. In tumor biology, the Hippo pathway is a prime example of signaling molecules involved in cancer progression and metastasis. Hippo core elements LATS1, [...] Read more.
The Hippo pathway is highly evolved to maintain tissue homeostasis in diverse species by regulating cell proliferation, differentiation, and apoptosis. In tumor biology, the Hippo pathway is a prime example of signaling molecules involved in cancer progression and metastasis. Hippo core elements LATS1, LATS2, MST1, YAP, and TAZ have critical roles in the maintenance of traditional tissue architecture and cell homeostasis. However, in cancer development, dysregulation of Hippo signaling results in tumor progression and the formation secondary cancers. Hippo components not only transmit biochemical signals but also act as mediators of mechanotransduction pathways during malignant neoplasm development and metastatic disease. This review confers knowledge of Hippo pathway core components and their role in cancer progression and metastasis and highlights the clinical role of Hippo pathway in cancer treatment. The Hippo signaling pathway and its unresolved mechanisms hold great promise as potential therapeutic targets in the emerging field of metastatic cancer research. Full article
(This article belongs to the Special Issue Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy)
►▼ Show Figures

Figure 1

23 pages, 1208 KiB  
Review
Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
by Inês Mendes and Nuno Vale
Biomedicines 2024, 12(1), 227; https://doi.org/10.3390/biomedicines12010227 - 19 Jan 2024
Cited by 2 | Viewed by 2297
Abstract
Gastrointestinal cancers (GICs) are one of the most recurrent diseases in the world. Among all GICs, pancreatic cancer (PC) is one of the deadliest and continues to disrupt people’s lives worldwide. The most frequent pancreatic cancer type is pancreatic ductal adenocarcinoma (PDAC), representing [...] Read more.
Gastrointestinal cancers (GICs) are one of the most recurrent diseases in the world. Among all GICs, pancreatic cancer (PC) is one of the deadliest and continues to disrupt people’s lives worldwide. The most frequent pancreatic cancer type is pancreatic ductal adenocarcinoma (PDAC), representing 90 to 95% of all pancreatic malignancies. PC is one of the cancers with the worst prognoses due to its non-specific symptoms that lead to a late diagnosis, but also due to the high resistance it develops to anticancer drugs. Gemcitabine is a standard treatment option for PDAC, however, resistance to this anticancer drug develops very fast. The microbiome was recently classified as a cancer hallmark and has emerged in several studies detailing how it promotes drug resistance. However, this area of study still has seen very little development, and more answers will help in developing personalized medicine. PC is one of the cancers with the highest mortality rates; therefore, it is crucial to explore how the microbiome may mold the response to reference drugs used in PDAC, such as gemcitabine. In this article, we provide a review of what has already been investigated regarding the impact that the microbiome has on the development of PDAC in terms of its effect on the gemcitabine pathway, which may influence the response to gemcitabine. Therapeutic advances in this type of GIC could bring innovative solutions and more effective therapeutic strategies for other types of GIC, such as colorectal cancer (CRC), due to its close relation with the microbiome. Full article
(This article belongs to the Special Issue Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop